Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas

Butterfly glioblastomas (bGBM), defined as tumours crossing the midline to involve hemispheres bilaterally, have a dismal prognosis with a median survival of 3.3-6 months and only 9% of patients with bGBM survive 2-years. These figures put bGBM in the worst end of the spectrum of GBM prognosis, significantly inferior to the survival figures quoted in the literature with standard of care - 14.6 months - particularly when 5-aminolevulinic acid is used as surgical adjuvant - 17.47 months. Despite the poor outcome of this disease, there is preliminary evidence suggesting that active oncology trea

Trial Details

NCT ID
NCT07384884
Phase
NA
Sponsor
King's College Hospital NHS Trust
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Presumptive diagnosis of bGBM as per preoperative MRI and MDT assessment
  • Presumed residual / smaller component of the bGBM has to be \< 2.5cm
  • Performance Status 0-1
  • Able to consent for the study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →